VVOS VIVOS THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, VIVOS THERAPEUTICS INC reported revenue of $5.15M (up 34.9% from a year earlier), net income of −$5.48M and diluted EPS of −$0.31; over the last four quarters revenue was $20.9M and net income −$25.5M; for the fiscal year ended December 2025 revenue was $17.4M, up 16.0% on the year before.
VVOS annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $17.4M, gross profit $10.5M, operating income −$19.9M, net income −$21.2M (margin -121.7%), EPS −$2.07
- Fiscal year ended Dec 2024: revenue $15.0M, gross profit $9.02M, operating income −$11.2M, net income −$11.1M (margin -74.1%), EPS −$2.22
- Fiscal year ended Dec 2023: revenue $13.8M, gross profit $8.27M, operating income −$17.3M, net income −$13.6M (margin -98.4%), EPS −$11.14
- Fiscal year ended Dec 2022: revenue $16.0M, gross profit $10.0M, operating income −$25.0M, net income −$23.8M (margin -148.8%), EPS −$25.90
- Fiscal year ended Dec 2021: revenue $16.9M, gross profit $12.6M, operating income −$20.4M, net income −$20.3M (margin -120.2%), EPS −$0.96
VVOS quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $5.15M (up 34.9% year over year), net income −$5.48M, EPS −$0.31
- Quarter ended Mar 31, 2026: revenue $5.14M (up 70.5% year over year), net income −$7.68M, EPS −$0.52
- Quarter ended Dec 31, 2025 (from the annual report): revenue $3.82M (up 3.4% year over year), net income −$6.95M, EPS −$0.58
- Quarter ended Sep 30, 2025: revenue $6.78M (up 75.7% year over year), net income −$5.40M, EPS −$0.49
- Quarter ended Jun 30, 2025: revenue $3.82M (down 5.8% year over year), net income −$5.01M, EPS −$0.55
- Quarter ended Mar 31, 2025: revenue $3.02M (down 11.8% year over year), net income −$3.86M, EPS −$0.45
- Quarter ended Dec 31, 2024 (from the annual report): revenue $3.70M (up 13.9% year over year), net income −$2.83M, EPS $0.41
- Quarter ended Sep 30, 2024: revenue $3.86M (up 16.9% year over year), net income −$2.62M, EPS −$0.40
- Quarter ended Jun 30, 2024: revenue $4.05M (up 19.4% year over year), net income −$1.93M, EPS −$0.60
- Quarter ended Mar 31, 2024: revenue $3.42M (down 11.4% year over year), net income −$3.76M, EPS −$1.63
- Quarter ended Dec 31, 2023 (from the annual report): revenue $3.25M (down 17.8% year over year), net income −$4.26M, EPS −$3.05
- Quarter ended Sep 30, 2023: revenue $3.30M (down 22.3% year over year), net income −$2.09M, EPS −$1.75
- Quarter ended Jun 30, 2023: revenue $3.40M (down 18.9% year over year), net income −$5.53M, EPS −$4.62
- Quarter ended Mar 31, 2023: revenue $3.86M (up 5.8% year over year), net income −$1.70M, EPS −$1.72
- Quarter ended Dec 31, 2022 (from the annual report): revenue $3.95M (down 10.1% year over year), net income −$6.09M, EPS −$18.92
- Quarter ended Sep 30, 2022: revenue $4.25M (down 6.6% year over year), net income −$5.43M, EPS −$6.40
- Quarter ended Jun 30, 2022: revenue $4.18M (down 7.0% year over year), net income −$6.99M, EPS −$0.33
- Quarter ended Mar 31, 2022: revenue $3.64M (up 5.7% year over year), net income −$5.33M, EPS −$0.25
- Quarter ended Dec 31, 2021 (from the annual report): revenue $4.39M, net income −$7.39M, EPS −$0.32
- Quarter ended Sep 30, 2021: revenue $4.55M, net income −$5.45M, EPS −$0.26
VVOS cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$15.3M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$12.7M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$11.9M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$19.6M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$15.7M, share buybacks n/a
VVOS balance sheet
- Jun 30, 2026: cash $1.77M, total assets $24.1M, total liabilities $28.1M, shareholders' equity −$3.82M, long-term debt $366K
- Mar 31, 2026: cash $2.11M, total assets $25.0M, total liabilities $26.3M, shareholders' equity −$1.14M, long-term debt $418K
- Dec 31, 2025: cash $2.03M, total assets $25.2M, total liabilities $26.7M, shareholders' equity −$1.49M, long-term debt $469K
- Sep 30, 2025: cash $3.09M, total assets $25.6M, total liabilities $23.1M, shareholders' equity $2.53M, long-term debt $8.38M
- Jun 30, 2025: cash $4.40M, total assets $26.0M, total liabilities $21.5M, shareholders' equity $4.58M, long-term debt $7.76M
- Mar 31, 2025: cash $2.34M, total assets $11.3M, total liabilities $6.88M, shareholders' equity $4.41M
- Dec 31, 2024: cash $6.26M, total assets $15.3M, total liabilities $7.33M, shareholders' equity $7.95M
- Sep 30, 2024: cash $6.31M, total assets $15.3M, total liabilities $7.68M, shareholders' equity $7.67M
What is VVOS's revenue?
VIVOS THERAPEUTICS INC reported $20.9M of revenue over its last four quarters, through June 30, 2026.
Is VVOS profitable?
No. VIVOS THERAPEUTICS INC lost $25.5M over the last four quarters.
What is VVOS's EPS?
Diluted earnings per share over the last four quarters were −$1.90; −$0.31 in the latest quarter.